Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients
Latest Information Update: 20 May 2020
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 May 2020 Results assessing cognition in natalizumab treated MS patients, presented at the 72nd Annual Meeting of the American Academy of Neurology
- 23 Jun 2015 Efficacy at 24 months, results presented at the 1st Congress of the European Academy of Neurology.
- 30 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.